In recent days, I’ve freed up about £500 of cash from sales of other investments. To that end, I’ve been thinking about how to invest it. I’m looking at buying two dividend shares, primarily to derive a passive income stream. Let’s take a closer look.
A smoking hot yield
For the six months to 31 March, the business reported that revenue fell by 1.3% and operating profit declined by 26.6%.
This is an indication of how wage and cost inflation are beginning to impact the company’s balance sheet. But I do consider this a short-term issue.
In the same report, net debt was down from £11bn to £9.7bn. This suggests that the firm is becoming leaner and increases the possibility of expansion projects, given the lighter debt pile.
Additionally, it paid an interim dividend of 42.54p per share, a 1% increase year on year.
The business has been focusing on investing in its sales across the UK, US, and Australia. In these regions, it’s seen 0.25% growth in aggregate market share.
What’s more, the firm has operating cash flow of £2.63bn, meaning that it should be able to overcome any issues that arise in the short term.
Solid sales growth
Second, GSK (LSE:GSK) paid a total dividend of 80p per share in 2021, amounting to a dividend yield of 7.42%. The shares are currently trading at 1,330.2p.
For the three months to 30 June, the pharmaceuticals firm announced that sales increased by 13%. This amounted to £6.9bn.
Furthermore, adjusted operating profit grew by 22% to £2bn. The business also stated that it was lifting its full-year guidance, while expecting full-year sales to grow between 6% and 8%. This growth, though, isn’t guaranteed.
As a potential investor, I find these recent results exciting and indicative of good times ahead for the company. These results come after the public listing of GSK’s consumer healthcare segment, Haleon.
GSK is, however, fighting litigation involving personal injury claims. These concern the Zantac heartburn drug. This case could potentially cost $17bn, but Citi says legal developments may reduce the firm’s exposure. The amount may be significantly less than this.
In any case, the business has operating cash flow of $10.51bn. This should enable the firm to sail through any difficulties that may arise from the litigation.
Overall, both of these companies are well-established and boast attractive dividend yields. Both are focused on expansion, which I consider appealing. As such, I’m going to take my £500 and buy the shares of both companies to target an income stream through dividends. I’ll be adding the shares to my portfolio soon.
The post With a spare £500, I’m buying these 2 top dividend shares appeared first on The Motley Fool UK.
The hotshot analysts at The Motley Fool UK’s flagship share-tipping service Share Advisor have just unveiled what they think could be the six best buys for investors right now.
And while timing isn’t everything, the average return of their previous stock picks shows that it could pay to get in early on their best ideas – particularly in this current climate!
What’s more, all six ‘Best Buys Now’ are available to access right now, in just a few clicks.
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
- How I’d invest £1,000 in September to generate passive income for life
- Best British growth stocks for September
- Best British shares to buy in September
- Looking for passive income? Here’s 1 top income stock with a 7%+ yield!
- Forget saving, I’m investing in these 2 FTSE stocks to try and double my money!
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Andrew Woods has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc and Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.